Form 4: 4D Molecular CFO Granted 480,000 Stock Options

Kristian Humer, Chief Financial Officer of 4D Molecular Therapeutics, Inc., was granted 480,000 stock options with an exercise price of $10.51, vesting over four years.

Summary

• Kristian Humer, Chief Financial Officer of 4D Molecular Therapeutics, Inc. (FDMT), was granted 480,000 stock options.
• The options have an exercise price of $10.51 per share.
• The grant date for these options was December 9, 2025.
• The options expire on December 8, 2035.
• The vesting schedule dictates that 25% of the shares vest on the first anniversary of November 17, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter, leading to full vesting on the fourth anniversary of the Vesting Commencement Date, contingent on continued service.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating retention efforts and alignment of interests. The Rule 10b5-1 plan adds transparency. No negative information is present.

Positives

• The grant of stock options to the CFO aligns management's incentives with long-term shareholder value creation.
• A Rule 10b5-1 plan indicates a pre-planned transaction, reducing concerns about opportunistic trading.

Risks

• The value of the stock options is contingent on the company's stock price appreciating above the exercise price of $10.51.
• The vesting schedule requires Kristian Humer to remain a service provider to the company for four years to fully realize the benefit of the options.

Future Outlook

The grant of long-term equity incentives suggests an expectation of continued service from the Chief Financial Officer and a focus on long-term value creation for the company.

Industry Context

Equity grants, particularly stock options with multi-year vesting schedules, are a common form of executive compensation in the biotechnology and pharmaceutical industries, aiming to retain key talent and align management interests with long-term company performance and shareholder returns.

Stakeholder Impact

• Shareholders: Potential for increased alignment between executive incentives and shareholder value.
• Employees: Standard executive compensation practices can positively influence morale and retention of key personnel.

Next Steps

• Kristian Humer will continue to serve as Chief Financial Officer, with the vesting of his stock options contingent on his ongoing service to the company.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, Kristian Humer, CFO, Stock Options, Executive Compensation, Insider Transaction, Form 4, Rule 10b5-1, Equity Grant